- Home
- BHE vs EWTX Comparison
BHE vs EWTX Comparison
Compare BHE & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHE
- EWTX
- Stock Information
- Founded
- BHE 1979
- EWTX 2017
- Country
- BHE United States
- EWTX United States
- Employees
- BHE N/A
- EWTX N/A
- Industry
- BHE Electrical Products
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- BHE Technology
- EWTX Health Care
- Exchange
- BHE Nasdaq
- EWTX Nasdaq
- Market Cap
- BHE 1.4B
- EWTX 1.6B
- IPO Year
- BHE 1990
- EWTX 2021
- Fundamental
- Price
- BHE $42.72
- EWTX $16.47
- Analyst Decision
- BHE Strong Buy
- EWTX Buy
- Analyst Count
- BHE 2
- EWTX 10
- Target Price
- BHE $46.50
- EWTX $37.90
- AVG Volume (30 Days)
- BHE 214.2K
- EWTX 717.3K
- Earning Date
- BHE 11-04-2025
- EWTX 11-06-2025
- Dividend Yield
- BHE 1.59%
- EWTX N/A
- EPS Growth
- BHE N/A
- EWTX N/A
- EPS
- BHE 1.05
- EWTX N/A
- Revenue
- BHE $2,588,733,000.00
- EWTX N/A
- Revenue This Year
- BHE $0.03
- EWTX N/A
- Revenue Next Year
- BHE $5.83
- EWTX N/A
- P/E Ratio
- BHE $40.82
- EWTX N/A
- Revenue Growth
- BHE N/A
- EWTX N/A
- 52 Week Low
- BHE $30.73
- EWTX $10.60
- 52 Week High
- BHE $52.57
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- BHE 62.80
- EWTX 59.00
- Support Level
- BHE $41.88
- EWTX $14.68
- Resistance Level
- BHE $43.09
- EWTX $15.59
- Average True Range (ATR)
- BHE 1.27
- EWTX 0.81
- MACD
- BHE 0.38
- EWTX 0.09
- Stochastic Oscillator
- BHE 94.41
- EWTX 88.81
About BHE Benchmark Electronics Inc.
Benchmark Electronics Inc is engaged in product designing, engineering services, technology solutions, and manufacturing services (electronic manufacturing services (EMS) and precision technology services). It serves various industries, including aerospace & defense (A&D), medical technologies, complex industrials, semiconductor capital equipment, next-generation telecommunications, and high-end computing. Its geographical segments are the Americas, Asia and Europe of which key revenue is derived from the Americas.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.